TY - T1 - Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study) SN - / UR - http://hdl.handle.net/10138/303577 T3 - A1 - PRINCIPAL Study Grp; Schmidinger, Manuela; Bamias, Aristotelis; Procopio, Giuseppe; Hawkins, Robert; Rodriguez Sanchez, Angel; Vazquez, Sergio; Srihari, Narayanan; Kalofonos, Haralabos; Bono, Petri; Pisal, Chaitali Babanrao; Hirschberg, Yulia; Dezzani, Luca; Ahmad, Qasim; Jonasch, Eric A2 - PB - Y1 - 2019 LA - eng AB - BackgroundReal-world data are essential to accurately assessing efficacy and toxicity of approved agents in everyday practice. PRINCIPAL, a prospective, observational study, was designed to confirm the real-world safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC). Subjects, Materials, and MethodsPatients with clear cell advanced/metastatic RCC and a clinical decision to initiate pazopanib treatment within 30days of enrollment were eligible. Primary objectives i... VO - IS - SP - OP - KW - Renal cell carcinoma; Pazopanib; Real-world; Observational; Tyrosine kinase inhibitor; DOUBLE-BLIND; PHASE-III; SUNITINIB; SURVIVAL; EVEROLIMUS; 3122 Cancers N1 - PP - ER -